Core Viewpoint - China Biotechnology Services (08037.HK) has entered into a subscription agreement with Fucheng Holdings Limited for the issuance of convertible bonds totaling $35 million, equivalent to approximately HKD 272.3 million, with a conversion price set at HKD 0.66 per share, representing a discount of about 16.46% from the closing price of HKD 0.79 on the agreement date [1] Group 1 - The total principal amount of the convertible bonds is $35 million, which will result in a maximum issuance of approximately 413 million shares, accounting for about 42.28% of the total shares outstanding as of the announcement date [1] - The net proceeds from the issuance of the convertible bonds are expected to be approximately $33.9 million [1] - The company plans to allocate 47.6% of the net proceeds for repaying other loans' principal and interest [1] Group 2 - 25.8% of the net proceeds will be used for the development and construction of a network of boron neutron capture therapy centers for cancer treatment [1] - 5.7% of the net proceeds will be allocated for research and development costs [1] - 20.9% of the net proceeds will be utilized for general working capital purposes [1]